America from its very origins was founded upon the pillar of individual property rights, with specific provisions in our Constitution addressing “takings” by eminent domain as well as unfair tax schemes which dilute the value of property. With the continued growth of government and the regulatory state, the rights of property owners has never faced a bigger threat. CASE is fully engaged in the fight to defend property from encroaching government control, and stands ready to vigorously defend land owners from those who seek to coerce or restrict them in the use and enjoyment of their land. Government schemes that target land for burdensome regulatory control or takings is entirely inconsistent with the ideals and benefits of the free market and the interests of America’s consumers.
Search
Categories
- Aegis
- Agriculture
- Commerce
- Communications
- Consumer Safety
- Data Privacy
- Economy
- Education
- Energy
- Entertainment
- Environment
- Financial Services
- Fiscal Policy
- Healthcare
- Higher Ed on the Hill
- Intellectual Property
- Kentucky
- Labor
- Legal
- Lifestyle
- Manufacturing
- Media
- Regulation
- Retail
- Robotexts
- Taxes
- TCPA
- Technology
- Trade
- Transportation
- Uncategorized
- Veterans
Archives
Contact Us
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/